ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS.

Details

Serval ID
serval:BIB_B23415647269
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS.
Journal
Clinical Microbiology and Infection
Author(s)
Lortholary O., Petrikkos G., Akova M., Arendrup M.C., Arikan-Akdagli S., Bassetti M., Bille J., Calandra T., Castagnola E., Cornely O.A., Cuenca-Estrella M., Donnelly J.P., Garbino J., Groll A.H., Herbrecht R., Hope W.W., Jensen H.E., Kullberg B.J., Lass-Flörl C., Meersseman W., Richardson M.D., Roilides E., Verweij P.E., Viscoli C., Ullmann A.J.
Working group(s)
ESCMID Fungal Infection Study Group
ISSN
1469-0691 (Electronic)
ISSN-L
1198-743X
Publication state
Published
Issued date
2012
Peer-reviewed
Oui
Volume
18
Number
Suppl. 7
Pages
68-77
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Abstract
Mucosal candidiasis is frequent in immunocompromised HIV-infected highly active antiretroviral (HAART) naive patients or those who have failed therapy. Mucosal candidiasis is a marker of progressive immune deficiency. Because of the frequently marked and prompt immune reconstitution induced by HAART, there is no recommendation for primary antifungal prophylaxis of mucosal candidiasis in the HIV setting in Europe, although it has been evidenced as effective in the pre-HAART era. Fluconazole remains the first line of therapy for both oropharyngeal candidiasis and oesophageal candidiasis and should be preferred to itraconazole oral solution (or capsules when not available) due to fewer side effects. For patients who still present with fluconazole-refractory mucosal candidiasis, oral treatment with any other azole should be preferred based on precise Candida species identification and susceptibility testing results in addition to the optimization of HAART when feasible. For vaginal candidiasis, topical therapy is preferred.
Pubmed
Web of science
Open Access
Yes
Create date
22/01/2013 17:10
Last modification date
20/08/2019 15:20
Usage data